Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody for EBV-HLH and CAEBV
NCT05039580Phase 4Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
A Phase 4 trial of PD-1 Monoclonal Antibody in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), chronic active Epstein-Barr virus infection (CAEBV), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)chronic active Epstein-Barr virus infection (CAEBV)
Beyond the preview
Go deeper on NCT05039580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039580.